# Drug Discovery
Latest news and articles about Drug Discovery
Total: 7 articles found
NVIDIA’s Digital Laboratory: BioNeMo and the Rise of Autonomous Science
NVIDIA has launched the BioNeMo Agent Toolkit, a comprehensive suite of AI tools and models designed to empower autonomous AI agents in life sciences research. The platform aims to accelerate scientific discovery by enabling AI to reason through data, run experiments, and collaborate directly with human scientists.
ByteDance’s Biological Breakout: Why the TikTok Maker is Spinning Off Its AI Drug Lab
ByteDance is spinning off its AI drug discovery unit into an independent entity to bridge the gap between high-speed internet culture and the slow-burn reality of pharmaceutical R&D. Despite technical breakthroughs in undruggable targets, the move reflects a strategic shift toward seeking external capital to fund long-cycle biotech ventures.
From Outsourcing to Outpacing: China’s Biotech Leap Triggers Alarm in Washington
Pfizer’s multi-billion dollar partnership with Innovent Biologics underscores China’s rapid ascent from a pharmaceutical follower to a global innovation hub. As Chinese firms begin to outperform Western incumbents in clinical trials and regulatory speed, Washington is increasingly viewing the biotech sector through a lens of national security and competition.
Standardizing the Pulse: China Sets New Benchmarks for Vessel-on-a-Chip Technology
China's market regulator has approved the first national standard for vessel-on-a-chip technology, effective May 2027. This framework establishes technical benchmarks for microfluidic vascular models, aiming to accelerate drug discovery and standardize bio-manufacturing processes across the country.
China’s Biotech Coming of Age: Hengrui and BMS Strike Record $15.2 Billion Alliance
Hengrui Pharmaceuticals and Bristol Myers Squibb have signed a landmark $15.2 billion strategic partnership to develop 13 early-stage drug candidates. The deal marks a record for Chinese biotech out-licensing and underscores the growing global reliance on Chinese innovation to replenish pharmaceutical pipelines.
OpenAI Steps into the Lab: GPT-Rosalind and the High-Stakes Battle for AI-Driven Cures
OpenAI has launched GPT-Rosalind, a specialized AI model for drug discovery, marking a direct challenge to Google's dominance in the life sciences sector. Partnering with industry leaders like Moderna and Amgen, OpenAI aims to leverage its generative technology to accelerate the translation of biological data into clinical medical applications.
The Algorithmic Apothecary: Insilico Medicine Nets High-Stakes AI Drug Pact with Eli Lilly
Insilico Medicine has entered a strategic collaboration with Eli Lilly to utilize generative AI for drug discovery, marking a significant milestone in the integration of AI into Big Pharma's R&D pipelines. The partnership validates Insilico's Pharma.AI platform and signals a broader industry shift toward algorithmic molecular design.